Temas de la conferencia Understand Mechanism of Action, Maximize Efficacy and Therapeutic Window, and Evaluate Long-Term Clinical Outcomes of Fc Receptor Pathway Targeting Biologics in Autoantibody Mediated Disease.
The field of FcRn receptor targeting is gaining ground-breaking speed as Argenx, Janssen, UCB and Immunovant compete to tackle myasthenia gravis and biopharma invest in transformative immunological therapy for autoimmune diseases as the next big drug opportunity.
La Sociedad Científica Hanson Wade
Observaciones Speakers: Basil Golding Director FDA/CBER, Hans de Haard Chief Scientific Officer Argenx, David Humphreys Senior Director and Head of New Modality Therapeutics Protein Sciences UCB, Tony Shock Director UCB and More.
